Additional file 1 of The efficacy and safety of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor, in patients with advanced head and neck mucosal melanoma harboring CDK4 amplification

Additional file 1: Tables S1-4. Table S1. Inhibitory effects of palbciclib and dalpiciclib on tumor growth in HNMM-PDX models. Table S2. Baseline clinical characteristics and previous systemic therapies. Table S3. Baseline and lowest level of neutrophil and white blood cell counts for each patient. Table S4. Tumor burden and patient outcomes.